Evidence map›Paper›PMID 25525343›Full record

ArticlePatient preference and adherence2014

Measuring patients' satisfaction with their anti-TNF treatment in severe Crohn's disease: scoring and psychometric validation of the Satisfaction for PAtients in Crohn's diseasE Questionnaire (SPACE-Q(©)).

Hélène Gilet, Benoit Arnould, Fatoumata Fofana, Pierre Clerson, Jean-Frédéric Colombel, Olivier D'Hondt, Patrick Faure, Hervé Hagège, Maria Nachury, Stéphane Nahon and 4 more

Abstract read
In one paragraph

Article in Patient preference and adherence, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Validation of a Patient-Created, Patient-Reported Experience Measure for Inflammatory Bowel Disease in the United Kingdom.Health expectations : an international journal of public participation in health care and health policy · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hélène GiletHEOR and Strategic Market Access, Mapi, Lyon, France.
Benoit ArnouldHEOR and Strategic Market Access, Mapi, Lyon, France.
Fatoumata FofanaHEOR and Strategic Market Access, Mapi, Lyon, France.
Pierre ClersonOrgamétrie, Roubaix, France.
Jean-Frédéric ColombelIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Olivier D'HondtOrgamétrie, Roubaix, France.
Patrick FaureClinique Saint-Jean du Languedoc, Toulouse, France.
Hervé HagègeCentre Hospitalier Intercommunal, Créteil, France.
Maria NachuryHôpital Claude Huriez, Lille, France.
Stéphane NahonCentre Hospitalier Intercommunal, Le Raincy Montfermeil, France.
Gilbert TucatGastroenterologist, Private Clinical Practice, Paris, France.
Luc VandrommeGastroenterologist, Private Clinical Practice, Reims, France.
Ines Cazala-TelingeAbbvie France, Rungis, France.
Emmanuel ThiboutAbbvie France, Rungis, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere Crohn's disease management includes anti-tumor necrosis factor (anti-TNF) drugs that differ from early-stage treatments regarding efficacy, safety, and convenience. This study aimed to finalize and psychometrically validate the Satisfaction for PAtients in Crohn's diseasE Questionnaire (SPACE-Q(©)), developed to measure satisfaction with anti-TNF treatment in patients with severe Crohn's disease.

methodsA total of 279 patients with severe Crohn's disease receiving anti-TNF therapy completed the SPACE-Q 62-item pilot version at inclusion and 12 and 13 weeks after first anti-TNF injection. The final SPACE-Q scoring was defined using multitrait and regression analyses and clinical relevance considerations. Psychometric validation included clinical validity against Harvey-Bradshaw score, concurrent validity against Treatment Satisfaction Questionnaire for Medication (TSQM), internal consistency reliability, test-retest reliability, and responsiveness against the patient global impression of change (PGIC).

resultsQuality of completion was good (55%-67% of patients completed all items). Four items were removed from the questionnaire. Eleven scores were defined within the final 58-item SPACE-Q: disease control; symptoms, anal symptoms, and quality of life transition scales; tolerability; convenience; expectation confirmation toward efficacy, side effects, and convenience; satisfaction with treatment; and motivation. Scores met standards for concurrent validity (correlation between SPACE-Q satisfaction with treatment and TSQM satisfaction scores =0.59), internal consistency reliability (Cronbach's α=0.67-0.93), test-retest reliability (intraclass correlations =0.62-0.91), and responsiveness (improvement in treatment experience assessed by the SPACE-Q for patients reporting improvement on the PGIC). Significantly different mean scores were observed between groups of patients with different Harvey-Bradshaw disease severity scores.

conclusionThe SPACE-Q is a valid, reliable, and responsive instrument to measure satisfaction with anti-TNF treatment in patients with severe Crohn's disease and for use in future studies.

Indexed as

anti-TNF treatmentCrohn’s diseasequestionnairesatisfaction

Identifiers

PMID25525343
PMCPMC4262217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.